STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Dec 2014 Planned primary completion date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 28 Apr 2014 Planned primary completion date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
- 08 Jul 2013 New trial record